Elimination of pancreatic secretory trypsin inhibitor from the circulation. A study in man. 1983

W H Marks, and K Ohlsson

The elimination of human pancreatic secretory trypsin inhibitor (PSTI) from the circulation of man has been examined in two human volunteers. Serial samplings of blood and urine were made for 55 h, after a rapid intravenous infusion of 125I-labeled human PSTI. The findings demonstrated a rapid initial elimination from the circulation. Within 30 min only 30% of the infused label remained (T1/2, 6 min). This was accompanied by the rapid appearance in the urine of radiolabel. Our results indicate that PSTI would prove a poor diagnostic marker for acute pancreatitis late in the course of the disease. This is opposed to the findings of Ogawa et al., who reported prolonged elevated circulating levels of PSTI weeks into the disease. However, they also noted rises of PSTI during acute pancreatitis in excess of 10 times the levels we have noted. Further exploration of population differences and the behavior of PSTI during acute pancreatitis are necessary to help resolve these findings.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D010195 Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis. Acute Edematous Pancreatitis,Acute Pancreatitis,Pancreatic Parenchyma with Edema,Pancreatic Parenchymal Edema,Pancreatitis, Acute,Pancreatitis, Acute Edematous,Peripancreatic Fat Necrosis,Acute Edematous Pancreatitides,Acute Pancreatitides,Edema, Pancreatic Parenchymal,Edematous Pancreatitides, Acute,Edematous Pancreatitis, Acute,Fat Necrosis, Peripancreatic,Necrosis, Peripancreatic Fat,Pancreatic Parenchymal Edemas,Pancreatitides, Acute,Pancreatitides, Acute Edematous,Parenchymal Edema, Pancreatic,Peripancreatic Fat Necroses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014359 Trypsin Inhibitor, Kazal Pancreatic A secreted KAZAL MOTIF-containing serine peptidase inhibitor that inhibits TRYPSIN. It is a protein composed of 56 amino acid residues and is different in amino acid composition and physiological activity from the Kunitz bovine pancreatic trypsin inhibitor (APROTININ). It protects against the trypsin-mediated premature activation of ENZYME PRECURSORS in the PANCREAS. Mutations in the SPINK1 gene are associated with CHRONIC PANCREATITIS. Acidic Pancreatic Trypsin Inhibitor,Kazal Pancreatic Trypsin Inhibitor,Pancreatic Secretory Trypsin Inhibitor, Kazal,Pancreatic Trypsin Secretory Inhibitor, Kazal,Trypsin Inhibitor, Pancreatic Secretory,Inhibitor, Tumor-Associated Trypsin,Pancreatic Secretory Trypsin Inhibitor,SPINK1,Serine Peptidase Inhibitor, Kazal-Type 1,Serine Protease Inhibitor Kazal-Type 1,Trypsin Inhibitor Kazal Pancreatic,Trypsin Inhibitor, Tumor-Associated,Tumor-Associated Trypsin Inhibitor,Serine Peptidase Inhibitor, Kazal Type 1,Serine Protease Inhibitor Kazal Type 1,Trypsin Inhibitor, Tumor Associated,Tumor Associated Trypsin Inhibitor
D014361 Trypsin Inhibitors Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. Trypsin Inhibitor,Inhibitor, Trypsin,Inhibitors, Trypsin

Related Publications

W H Marks, and K Ohlsson
June 2010, World journal of gastrointestinal pathophysiology,
W H Marks, and K Ohlsson
February 1995, Nihon rinsho. Japanese journal of clinical medicine,
W H Marks, and K Ohlsson
January 1976, Methods in enzymology,
W H Marks, and K Ohlsson
November 2004, Nihon rinsho. Japanese journal of clinical medicine,
W H Marks, and K Ohlsson
August 1999, Nihon rinsho. Japanese journal of clinical medicine,
W H Marks, and K Ohlsson
January 1988, Advances in experimental medicine and biology,
W H Marks, and K Ohlsson
September 1984, Clinica chimica acta; international journal of clinical chemistry,
W H Marks, and K Ohlsson
October 1989, Hinyokika kiyo. Acta urologica Japonica,
W H Marks, and K Ohlsson
September 1985, Journal of biochemistry,
Copied contents to your clipboard!